APITBIO

About APITBIO

APITBIO, a South Korean biotechnology firm established in 2018 by founder and CEO Seon-Joo Yoon, is focused on the development of antibody-based therapeutics. The company is strategically positioned within the oncology and infectious disease markets, aiming to fulfill unmet medical needs. APITBIO operates from its headquarters in Seoul and has secured funding from institutional investors, including Hyundai Venture Investment, Shinhan Venture Investment, and UTC Investment.

The company's business model centers on the research, development, and eventual commercialization of its therapeutic pipeline. This involves a comprehensive process that spans antibody screening, discovery, optimization, and production. APITBIO's core technology is a proprietary human synthetic antibody (Fab) library, which is utilized to discover and engineer various antibody-based treatments. The portfolio includes first-in-class monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). The company also offers services related to its antibody discovery and construction platforms.

A key asset in APITBIO's pipeline is APB-A001, a human antibody targeting L1CAM (CD171), a protein overexpressed in several intractable solid tumors. This product has received approval for a Phase 1 clinical trial in Korea. The company is also developing treatments for chronic hepatitis B and advancing diagnostic kits for pancreatic and biliary tract cancers. Strategic collaborations are a core component of APITBIO's strategy. A notable partnership with Samjin Pharmaceuticals aims to co-develop new ADC therapies by combining APITBIO's antibody expertise with Samjin's linker-payload technology. The company has also entered into a joint development agreement with China-based Biotheus to create immuno-oncology bispecific antibodies, leveraging the strengths of both entities to target solid tumors.